- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 11, Issue 25, 2005
Current Pharmaceutical Design - Volume 11, Issue 25, 2005
Volume 11, Issue 25, 2005
-
-
Editorial [Hot Topic: Capabilities of PET and SPECT in Pre-Clinical and Clinical Research (Executive Editor: Michael Kassiou)]
More LessDrug discovery and development is time consuming and a costly procedure. The challenges for pharmaceutical companies range from the evaluation of potential new drug candidates, the determination of drug pharmacokinetics/pharmacodynamics, the measurement of receptor occupancy as a determinant of drug efficacy, and the pharmacological characterisation of mechanisms of action. Radiolabelled molecul Read More
-
-
-
PET Imaging in Clinical Drug Abuse Research
Authors: S. J. Gatley, N. D. Volkow, G.- J. Wang, J. S. Fowler, J. Logan, Y.- S. Ding and M. GerasimovOver the last two decades, SPECT (single photon emission computed tomography) and especially PET (positron emission tomography) have proven increasingly effective imaging modalities in the study of human psychopharmacology. Abusing populations can be studied at multiple times after abstinence begins, to give information about neurochemical and physiological adaptations of the brain during recovery from addiction. I Read More
-
-
-
Fluorine-18-Labelled Fluoropyridines: Advances in Radiopharmaceutical Design
By F. DollePositron Emission Tomography is a high-resolution, sensitive, functional imaging technique, which can efficiently give access to the distribution, pharmacokinetics and -dynamics of a drug in vivo and which can therefore advantageously play a key-role in both drug discovery and development. This molecular imaging technique requires the preparation of a positron-emitting radiolabelled probe or radiotracer and f Read More
-
-
-
PET and SPECT Exploration of Central Monoaminergic Transporters for the Development of New Drugs and Treatments in Brain Disorders
Authors: D. Guilloteau and S. ChalonMembrane and vesicular monoaminergic transporters, responsible for the homeostasis of neurotransmitter pools at nerve endings, are very involved in the physiology and diseases of central nervous system. Recent progresses of cerebral molecular imaging using SPECT and PET methods allow the extend of in vivo exploration of these transporters. For this aim, an increasing number of radiopharmaceuticals labelled with [1 Read More
-
-
-
Small Animal Imaging in Drug Development
Authors: M. G. Pomper and J. S. LeeBetter mechanistic understanding of disease through mapping of the human and mouse genomes enables rethinking of human infirmity. In the case of cancer, e.g., we may begin to associate disease states with their underlying genetic defects rather than with the organ system involved. That will enable more selective, nontoxic therapies in patients who are genetically predisposed to respond to them. Because one of the Read More
-
-
-
Editorial [Hot Topic: Perspectives of New Antihypertensive Drugs (Executive Editor: Ji-Guang Wang)]
More LessHypertension is one of the most powerful cardiovascular risk factors. By lowering blood pressure, antihypertensive drug treatment reduces the incidence of stroke and coronary heart disease. In general, the currently recommended antihypertensive agents (α-blockers, angiotensin converting-enzyme inhibitors, angiotensin type-1 receptor blockers, β-blockers, calciumchannel blockers, and diuretics) provide similar c Read More
-
-
-
The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Authors: L. Magy, F. Vincent, Sebastien Faure, F. H. Messerli, J. G. Wang, J. M. Achard and A. FournierDuring the last 20 years, the renin-angiotensin system (RAS) has become an increasingly important focus of basic and clinical cardiovascular research. One main conceptual step forward was made with the discovery of a tissue RAS and the understanging of its critical pathophysiological role in atherogenesis and plaque destabilisation [1]. Major effort to find new strategies for blocking the RAS has produced new classes of Read More
-
-
-
Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
More LessVasopeptidase inhibition is a novel treatment approach in cardiovascular disease such as hypertension and heart failure. Since the inhibition of the angiotensin-converting enzyme (ACE) turned out to represent a very successful principle in the treatment of hypertension in numerous large scale clinical studies, their results encouraged attempts to inhibit other key enzymes in the regulation of vascular tone as well - such as the ne Read More
-
-
-
Ouabain Antagonists as Antihypertensive Agents
Authors: M. Ferrandi, P. Barassi, I. Molinari, L. Torielli, G. Tripodi, E. Minotti, G. Bianchi and P. FerrariThe evidence that high levels of endogenous ouabain (EO), a closely related isomer of ouabain, are implicated in human hypertension and cardiac hypertrophy and failure stimulated the pharmacological research for developing novel anti-hypertensive agents active as ouabain antagonists. The pathogenetic mechanisms through which increased EO levels affect cardiovascular system involve the modulation of Na-K ATPase, the k Read More
-
-
-
Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Authors: R. A. Augustyniak, G. D. Thomas, R. G. Victor and W. ZhangNitric oxide (NO) is thought to reduce blood pressure by evoking vasodilation either directly by causing relaxation of vascular smooth muscle or indirectly by acting in the rostral brainstem to reduce central sympathetic outflow, which decreases the release of norepinephrine from sympathetic nerve terminals. An increasingly large body of literature suggests that alterations in the NO system may play an important r Read More
-
-
-
Large Artery Stiffness and Antihypertensive Agents
Authors: J. Blacher, Athanase D. Protogerou and M. E. SafarPurpose of Review: Since in hypertensive populations, concentration on peripheral blood pressure only does not achieve 100% of blood pressure-attributable risk reduction, taking into consideration other hemodynamic parameters than peripheral blood pressure could perhaps improve cardiovascular prevention. The main purpose of this review is to analyse the scientific data in favour of considering arterial stiffness par Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
